Martin Johnson, MD
Pulmonary Disease · Salem, ORNPI 1922116557
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by GSK at 36.2% of the total.
Across 219 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Insmed, Inc.$287
- Merck$267
- United Therapeutics Corporation$193
- AstraZeneca$153
- Harmony Biosciences LLC$123
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,41894%
- Education$2006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 98 | $1,310 |
| Insmed, Inc. | 18 | $287 |
| Merck | 14 | $267 |
| United Therapeutics Corporation | 9 | $193 |
| AstraZeneca | 10 | $153 |
| Harmony Biosciences LLC | 2 | $123 |
| Boehringer Ingelheim | 7 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Sunovion Pharmaceuticals Inc. | 6 | $98 |
| Mylan Specialty L.p. | 5 | $73 |
| Phathom Pharmaceuticals, Inc. | 2 | $65 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $59 |
| Philips North America LLC | 4 | $58 |
| Genentech USA, Inc. | 3 | $58 |
| Amgen | 3 | $53 |
| Inspire Medical Systems, Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Baxter Healthcare | 2 | $47 |
| Electromed, Inc. | 3 | $44 |
| Arbor Pharmaceuticals, Inc. | 3 | $42 |
| Gilead | 3 | $42 |
| Sanofi | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Viatris Specialty LLC | 1 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| EUSA Pharma (US) LLC | 2 | $24 |
| Grifols USA, LLC | 2 | $24 |
| AbbVie | 1 | $23 |
| Genentech, Inc. | 1 | $23 |
| Itamar Medical Inc | 1 | $19 |
| Bayer | 1 | $17 |
| Abiomed | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $16 |
| Strongbridge US Inc. | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $12 |
| Actelion Pharmaceuticals US, Inc. | 1 | $11 |
How this compares
$3,618 in reported general payments places this provider in the 75th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 219 | $177,963 |
| OfevNintedanib Esylate | 22 | $140,525 |
| XolairOmalizumab | 33 | $101,114 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 125 | $94,134 |
| NucalaMepolizumab | 24 | $88,982 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 108 | $69,960 |
| Spiriva RespimatTiotropium Bromide | 97 | $63,991 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 75 | $41,715 |
| Dupixent PenDupilumab | 11 | $40,011 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 70 | $21,827 |
| OxycontinOxycodone Hcl | 13 | $18,912 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 108 | $18,332 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $18,183 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $16,540 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $14,263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat, Striverdi Respimat | $114 | $320,175318 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,310 | $316,250331 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $153 | $108,397164 claims |
| Genentech, Inc.Xolair | $23 | $101,11433 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $42 | $13,00224 claims |
| MerckDulera | $267 | $11,59728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 154 pulmonary disease providers in Oregon.
Other pulmonary disease in Salem
- Kamran FirooziSalem$9K
- Steven MarvelSalem$8K
- Nimeshkumar MehtaSalem$7K
- Bijaya ShresthaSalem$4K
- Yasaman EslaamizaadSalem$3K
- Kavan RamachandranSalem$3K
- Fayez BaderSalem$2K
- James ParosaSalem$1K
- Stephen YauPortland$984K
- Jeremy FeldmanBend$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.